Cargando…

Fedratinib Attenuates Bleomycin-Induced Pulmonary Fibrosis via the JAK2/STAT3 and TGF-β1 Signaling Pathway

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease with multiple causes, characterized by excessive myofibrocyte aggregation and extracellular matrix deposition. Related studies have shown that transforming growth factor-β1 (TGF-β1) is a key cytokine causing fibr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruan, Hao, Luan, Jiaoyan, Gao, Shaoyan, Li, Shuangling, Jiang, Qiuyan, Liu, Rui, Liang, Qing, Zhang, Ruiqin, Zhang, Fangxia, Li, Xiaohe, Zhou, Honggang, Yang, Cheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347567/ https://www.ncbi.nlm.nih.gov/pubmed/34361644 http://dx.doi.org/10.3390/molecules26154491

Ejemplares similares

Deglycosylated Azithromycin Attenuates Bleomycin-Induced Pulmonary Fibrosis via the TGF-β1 Signaling Pathway
por: Ruan, Hao, et al.
Publicado: (2021)

PKM2 promotes pulmonary fibrosis by stabilizing TGF-β1 receptor I and enhancing TGF-β1 signaling
por: Gao, Shaoyan, et al.
Publicado: (2022)

Regorafenib-Attenuated, Bleomycin-Induced Pulmonary Fibrosis by Inhibiting the TGF-β1 Signaling Pathway
por: Li, Xiaohe, et al.
Publicado: (2021)

Imrecoxib attenuates bleomycin-induced pulmonary fibrosis in mice
por: Miao, Yang, et al.
Publicado: (2023)

Antifibrotic Mechanism of Cinobufagin in Bleomycin-Induced Pulmonary Fibrosis in Mice
por: Li, Xiaohe, et al.
Publicado: (2019)

Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
por: Jamieson, Catriona, et al.
Publicado: (2015)

Baricitinib Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice by Inhibiting TGF-β1 Signaling Pathway
por: Gu, Songtao, et al.
Publicado: (2023)

Antifibrotic mechanism of avitinib in bleomycin-induced pulmonary fibrosis in mice
por: Miao, Yang, et al.
Publicado: (2023)

JAK2 Inhibition by Fedratinib Reduces Osteoblast Differentiation and Mineralisation of Human Mesenchymal Stem Cells
por: AlMuraikhi, Nihal, et al.
Publicado: (2021)

Clinical Utility of Fedratinib in Myelofibrosis
por: Waksal, Julian A, et al.
Publicado: (2021)

Duvelisib attenuates bleomycin‐induced pulmonary fibrosis via inhibiting the PI3K/Akt/mTOR signalling pathway
por: Li, Xiaohe, et al.
Publicado: (2023)

TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
por: Wu, Dandan, et al.
Publicado: (2020)

Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures
por: Singer, Jack W., et al.
Publicado: (2019)

Feifukang ameliorates pulmonary fibrosis by inhibiting JAK-STAT signaling pathway
por: Li, Hongbo, et al.
Publicado: (2018)

A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
por: Pardanani, A, et al.
Publicado: (2015)

Blocking follistatin-like 1 attenuates bleomycin-induced pulmonary fibrosis in mice
por: Dong, Yingying, et al.
Publicado: (2015)

TGF‐β/Smad and JAK/STAT pathways are involved in the anti‐fibrotic effects of propylene glycol alginate sodium sulphate on hepatic fibrosis
por: Xu, Shizan, et al.
Publicado: (2020)

Kangfuxin Oral Liquid Attenuates Bleomycin-Induced Pulmonary Fibrosis via the TGF-β1/Smad Pathway
por: Yao, Huan, et al.
Publicado: (2019)

Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts
por: Harrison, Claire N., et al.
Publicado: (2022)

The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis
por: Palmer, Jeanne, et al.
Publicado: (2020)

Hyperoside Attenuates Bleomycin-Induced Pulmonary Fibrosis Development in Mice
por: Huang, Jizhen, et al.
Publicado: (2020)

Biodegradable Nanoparticles Mediated Co-delivery of Erlotinib (ELTN) and Fedratinib (FDTN) Toward the Treatment of ELTN-Resistant Non-small Cell Lung Cancer (NSCLC) via Suppression of the JAK2/STAT3 Signaling Pathway
por: Chen, Donglai, et al.
Publicado: (2018)

2-aminopurine suppresses the TGF-β1-induced epithelial–mesenchymal transition and attenuates bleomycin-induced pulmonary fibrosis
por: Weng, Dong, et al.
Publicado: (2018)

Hydrogen sulfide attenuates myocardial fibrosis in diabetic rats through the JAK/STAT signaling pathway
por: Liu, Maojun, et al.
Publicado: (2018)

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
por: Ogasawara, Ken, et al.
Publicado: (2019)

Pinocembrin Ameliorates Skin Fibrosis via Inhibiting TGF-β1 Signaling Pathway
por: Li, Xiaohe, et al.
Publicado: (2021)

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor
por: Gangat, Naseema, et al.
Publicado: (2023)

Polydatin prevents bleomycin-induced pulmonary fibrosis by inhibiting the TGF-β/Smad/ERK signaling pathway
por: Liu, Yan-Lu, et al.
Publicado: (2020)

Curdione ameliorates bleomycin-induced pulmonary fibrosis by repressing TGF-β-induced fibroblast to myofibroblast differentiation
por: Liu, Peng, et al.
Publicado: (2020)

Dihydroartemisinin attenuates pulmonary inflammation and fibrosis in rats by suppressing JAK2/STAT3 signaling
por: You, Xiaolan, et al.
Publicado: (2022)

Atractylodin Suppresses TGF-β-Mediated Epithelial-Mesenchymal Transition in Alveolar Epithelial Cells and Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice
por: Chang, Kai-Wei, et al.
Publicado: (2021)

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2019)

Combination of Salvia miltiorrhiza and ligustrazine attenuates bleomycin-induced pulmonary fibrosis in rats via modulating TNF-α and TGF-β
por: Huang, Chengliang, et al.
Publicado: (2018)

Wenfei Buqi Tongluo Formula Against Bleomycin-Induced Pulmonary Fibrosis by Inhibiting TGF-β/Smad3 Pathway
por: Ding, Lu, et al.
Publicado: (2022)

Astragaloside IV modulates TGF‐β1‐dependent epithelial‐mesenchymal transition in bleomycin‐induced pulmonary fibrosis
por: Qian, Weibin, et al.
Publicado: (2018)

Correction to: Curdione ameliorates bleomycin-induced pulmonary fibrosis by repressing TGF-β-induced fibroblast to myofibroblast differentiation
por: Liu, Peng, et al.
Publicado: (2023)

ErHuang Formula Improves Renal Fibrosis in Diabetic Nephropathy Rats by Inhibiting CXCL6/JAK/STAT3 Signaling Pathway
por: Shen, Yu-Li, et al.
Publicado: (2020)

JAK-STAT and bone metabolism
por: Li, Jiliang
Publicado: (2013)

Antiflammin-1 attenuates bleomycin-induced pulmonary fibrosis in mice
por: Liu, Wei, et al.
Publicado: (2013)

miR-150-Based RNA Interference Attenuates Tubulointerstitial Fibrosis through the SOCS1/JAK/STAT Pathway In Vivo and In Vitro
por: Luan, Junjun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2ie4jqahv0t312ep08rdrs4us0